OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Saltz Discusses FOLFIRINOX in Colorectal Cancer

January 17th 2018

Leonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.

Dr. Erhunmwunsee Discusses Disparities in Lung Cancer Treatment

January 17th 2018

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

Dr. Abou-Alfa Discusses Treatment Options in Liver Cancer

January 17th 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in liver cancer.

Dr. Voss Discusses Treatment in the Neoadjuvant Setting for Kidney Cancer

January 16th 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment in the neoadjuvant setting for patients with kidney cancer.

Dr. Plimack on Choosing a Checkpoint Inhibitor in Bladder Cancer

January 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses choosing a checkpoint inhibitor in bladder cancer.

Dr. Martin on Choosing Treatments for Multiple Myeloma

January 16th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses choosing treatments for patients with multiple myeloma.

Dr. Borgen Discusses Trials in Neoadjuvant HER2+ Breast Cancer

January 16th 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses clinical trials in neoadjuvant HER2 breast cancer.

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

January 15th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of afatinib (Gilotrif) for the frontline treatment of patients with metastatic non

Dr. Oh Discusses Immunotherapy in Prostate Cancer

January 13th 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Dr. Ghamande on the AIM2CERV Trial in Cervical Cancer

January 13th 2018

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

Dr. Janjigian on Conducting MSI Testing in Gastric Cancer

January 13th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses when to conduct microsatellite instability (MSI) testing for patients with gastric cancer.

Dr. Eads Discusses the Classification of Gastrointestinal NETs

January 12th 2018

Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal neuroendocrine tumors.

Dr. Agarwal on the Advantages of Docetaxel in Prostate Cancer

January 12th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

Dr. Jain on the Combination of Venetoclax and Ibrutinib in CLL

January 12th 2018

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

Dr. Brufsky on the FDA Approval of Olaparib in BRCA+ Breast Cancer

January 12th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the FDA approval of olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.

Dr. Kaplan Discusses Rituximab Maintenance in MCL

January 11th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses remaining questions with rituximab (Rituxan) maintenance for patients with mantle cell lymphoma (MCL).

Dr. Sessa on the Management of BRCA1/2 Mutations in Ovarian Cancer

January 11th 2018

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses the management of BRCA1/2 mutations in patients with ovarian cancer.

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC

January 11th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

Dr. Sweeney Discusses Tailoring Treatment in Prostate Cancer

January 11th 2018

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses tailoring treatment to individual patients with prostate cancer.

Dr. Maloney Discusses Response to JCAR017 CAR T-Cell Therapy

January 11th 2018

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses responses to the chimeric antigen receptor (CAR) T-cell product JCAR017.